Not all journals are equally created or published. In a moment, we will look at how a highly respected journal handled this article. FIRST, a look at the policies of the group of journals you cited. Authors PAY the publisher to have their article included. Second, their review process is described, once you dig far enough; let's just say it is "interesting". Often, such journals are intended to serve the academic community, sharing early research that is not ready for prime time.
American Association for Cancer Research
To defray publication costs and to support other AACR programs, authors of accepted manuscripts will be invoiced based on the journal’s publication and color fees as detailed herein. Authors are required to confirm at the time of submission that they agree to pay the article publication fees in the event that their manuscript is accepted for publication.
The standard fees charged for publication include a flat publication fee based on the journal and article type and an additional handling fee for each color figure. These fees are detailed below.
Publication fee: $2,500 for all article types
Color fee: $450 per figure.
Cancer Research, Clinical Cancer Research
Publication fee: $1,500 for Research Articles ($1,100 for Brief Reports and all other article types)
Color fee: $675 per figure.
Cancer Immunology Research, Molecular Cancer Research, Molecular Cancer Therapeutics
Publication fee: $1,200 for Research Articles and Reviews ($1,000 for all other article types)
Color fee: $625 per figure.
THEN, look at how The Journal of Urology of the American Urology Association, a highly respected publication, review the information. After a short abstract, the Journal editors added a BOLD FACE, LARGE TYPE editorial comment, as follows:
Allyl isothiocyanate is particularly abundant in mustard, horseradish and wasabi, and it is mainly responsible for the pungent flavor of these vegetables. Allyl isothiocyanate is synthesized and stored as sinigrin (a glucosinolate) and is subsequently generated from the latter through myrosinase catalyzed hydrolysis of sinigrin. Myrosinase coexists with sinigrin in vegetables but glucosinolate hydrolysis does not normally occur until the vegetable is damaged, such as by insect chewing, fungal invasion, chopping and human mastication. Myrosinase activity also exists in the intestinal microflora in animals and humans, and glucosinolates that escape the action of vegetable myrosinase may be hydrolyzed in vivo. The authors show that allyl isothiocyanate rich mustard seed powder possesses potent anticancer activity in cultured bladder cancer cells and an orthotopic rat bladder cancer model in vivo, and that the mustard seed powder matrix has no effect on absorption and urinary excretion of allyl isothiocyanate. However, allyl isothiocyanate yield in vivo is extremely low in animals given purified sinigrin, indicating poor conversion from sinigrin to allyl isothiocyanate by the myrosinase like enzyme in the intestinal microflora. If not hydrolyzed by myrosinase, sinigrin has no anticancer activity.
The anticancer effect of MSP-1 was accompanied by modulation of multiple well-known cancer therapeutic targets, including activation of caspase-3, cleavage of polyadenosine diphosphate ribose polymerase, and down-regulation of cyclin B1 and vascular endothelial growth factor. Comparison of dose response in vivo between inhibition of tumor growth and muscle invasion by MSP-1 and its modulation of the aforementioned proteins suggests that down-regulation of vascular endothelial growth factor may be critical for MSP-1 to inhibit tumor invasion into the muscle. Taken together, MSP-1 is a highly promising substance for prevention and treatment of bladder cancer. Further preclinical and clinical evaluation of this substance is warranted."
Unfortunately, not everything posted to the net has been vetted. When doing our own research it becomes OUR duty to verify the reputation of the presenter, the publisher, the institution(s) mentioned, and the individual researchers. We must also understand the target audience and the intended USE of the information offered. We must look to the history of the information, progression over time, and the extent or lack of extent of peer confirmation and acceptance.
6/2015 HG Papillary & CIS
3 Years and 30 BCG/BCG+Inf
Tis CIS comes back.
BC clear as of 5/17 !
RCC found in my one & only kidney 10/17
Begin Chemo; Cisplatin and Gemzar
8/18 begin Chemo# 3
Begin year 4 with cis
2/19 Chemo #4
9/19 NED again
1/2020 CIS is back
Tried Keytruda, stopped by side effects
Workin on a new plan for 2021
None of this has been shown in patients with bladder cancer. These studies have all been done in rats or In tissue culture and are extremely preliminary. In addition they are seven years old and nothing clinically relevant appears to have been published . The scientific literature is full of studies like these which simply show directions in which a lot of additional research needs to be
done before we have any idea that this might be useful.
Diagnosis 2-08 Small papillary TCC; CIS
BCG; BCG maintenance
Vice-President, American Bladder Cancer Society